Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $5 million, down from $5.4 million in Q2 2025 and $7.4 million in Q3 2024, reflecting a shift from one-time revenue streams to long-term annual recurring revenue [23][24] - GAAP gross margin improved to 60%, up from 55% in Q2 2025 and 52% in Q3 2024, while non-GAAP gross margin remained above 80% since early 2024 [24] - Operating expenses decreased by $17.2 million, or 31%, in the first nine months of 2025, and by $3.4 million, or 21%, in Q3 compared to the prior year [24] Business Line Data and Key Metrics Changes - The company serves over 125 clients, with 45 new accounts signed year-to-date in 2025, surpassing the goal of 40 new accounts [8][12] - More than 50% of new clients have chosen the multi-condition solution, indicating a strong market preference for integrated offerings [11][12] - The average employer account size has nearly doubled compared to last year, contributing to revenue momentum [12] Market Data and Key Metrics Changes - The 2026 pipeline has grown to $69 million, with a target of $12.4 million in new business for implementation in 2026 [11][12] - The company has established partnerships with major health plans and channel partners, reaching over 116 million covered lives [13][14] Company Strategy and Development Direction - DarioHealth aims to transition to a high-margin recurring revenue model, focusing on integrated multi-condition platforms that deliver measurable outcomes [10][27] - The company is expanding its capabilities through strategic collaborations, such as partnerships with OneStep and GreenKey Health, to enhance its service offerings [18][19] - The company is also targeting opportunities in the public sector, driven by policy tailwinds favoring digital health solutions [16][49] Management's Comments on Operating Environment and Future Outlook - Management expects to reach cash flow breakeven by late 2026 to early 2027, supported by a healthy pipeline and operational efficiencies [25][27] - The company is experiencing stronger demand than ever, particularly from blue-chip employers and national insurers [11][12] - Management highlighted the importance of their technology platform as a strategic asset that supports high-margin recurring revenues [27] Other Important Information - The company completed a $17.5 million private placement, enhancing its financial position and signaling investor confidence [22] - DarioHealth is in the process of simplifying its capital structure and enhancing financial resilience through amendments to its credit agreement [22] Q&A Session Summary Question: What is the expected contribution from UnitedHealth's national rollout in 2026? - Management indicated that the rollout is innovative and will be implemented in chunks, but specific revenue contributions from this client were not disclosed [30][31] Question: What is driving the sequential declines in B2B2C revenue? - The decline is primarily attributed to the non-renewal of a large contract with a national health plan and the transition of the pharma business to a recurring revenue model [36][37] Question: Can you provide an update on the pharma services pipeline? - The company is focusing on a recurring revenue model in pharma services and expects to sign two to four accounts that will contribute to revenue next year [39][41] Question: How has the product-market fit and pricing model changed? - The company has adjusted its offerings based on claims-based analytics and engaged new partners to enhance its product solutions, which has improved market fit [44][45]